Oncology – Urological
RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association
8 May, 2023 | 13:02h | UTC
Commentary on Twitter
NEW: Final results from two randomised ph 3 trials of the STAMPEDE platform protocol suggest that enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. #pcsmhttps://t.co/P1uqzE4Wsv pic.twitter.com/l8U7DQZIoe
— The Lancet Oncology (@TheLancetOncol) May 4, 2023
21-y clinical trial update | Effects of a PSA–based screening on morbidity and mortality of prostate cancer
5 May, 2023 | 14:56h | UTC
AUA/SUO Guideline | Part I – Early detection of prostate cancer: prostate cancer screening
2 May, 2023 | 13:49h | UTC
AUA/SUO Guideline | Part II – Early detection of prostate cancer: considerations for a prostate biopsy
2 May, 2023 | 13:47h | UTC
AUA/SUO Guideline | Diagnosis and management of non-metastatic upper tract urothelial carcinoma
2 May, 2023 | 13:44h | UTC
AUA/SUO Guideline | Updates to Advanced Prostate Cancer
2 May, 2023 | 13:46h | UTCUpdates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) – The Journal of Urology
Clinical trial 2y update | Avelumab first-line maintenance for advanced urothelial carcinoma
2 May, 2023 | 13:30h | UTCOriginal Article: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma – New England Journal of Medicine
Single-arm trial | Retroperitoneal lymph node dissection as first-line treatment for early metastatic seminoma shows 81% 2-Year RFS
28 Apr, 2023 | 13:02h | UTCCommentary: Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma – The ASCO Post
Review | Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance
25 Apr, 2023 | 14:35h | UTCRisk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance – Journal of Urology (free PDF for a limited period)
Related:
Low-Value Prostate-Specific Antigen Screening in Older Males – JAMA Network Open
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life
25 Apr, 2023 | 14:34h | UTC
M-A | 5-alpha-reductase inhibitors are not associated with increased risk of mortality from prostate cancer
24 Apr, 2023 | 13:30h | UTCAssociation Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)
Commentary on Twitter
Systematic review & meta-analysis drawing on 2 decades of epidemiologic literature and including data from over 3 million patients shows no significant association between use of 5-alpha reductase inhibitor use and mortality from prostate cancer. https://t.co/3l9jT1l2P9 #PCSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
ASCO Guideline Update | Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
18 Apr, 2023 | 12:54h | UTC
RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer
18 Apr, 2023 | 12:52h | UTC
RCT | Effects of focal vs. extended irreversible electroporation ablation of localized prostate cancer
12 Apr, 2023 | 13:05h | UTCEffect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Irreversible electroporation (IRE) can provide promising oncological control as a focal therapy for patients with localized low-intermediate risk prostate cancer patients. https://t.co/lmYnYpSRmY
— JAMA Surgery (@JAMASurgery) February 1, 2023
Phase 2 RCT | Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer
10 Apr, 2023 | 13:41h | UTCAddition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Randomized trial of intermittent hormone therapy +/- radiation to oligometastatic sites of #prostatecancer shows significantly improved PFS & assoc time off hormone therapy & w/normal testosterone from combination. https://t.co/ZnmkQuqHZm #RadOnc #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) April 6, 2023
ESMO Guideline | Updated treatment recommendations for prostate cancer
6 Apr, 2023 | 13:18h | UTC
Guideline | Muscle-invasive and metastatic bladder cancer
6 Apr, 2023 | 13:19h | UTCMuscle-invasive and Metastatic Bladder Cancer – European Association of Urology (see PDF)
RCT | Enzalutamide versus standard antiandrogen therapy in hormone-sensitive prostate cancer with metastasis
5 Apr, 2023 | 13:30h | UTCTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
News Release: ENZAMET shows promise as prostate cancer treatment – University of Adelaide
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
15 Mar, 2023 | 15:24h | UTCSummary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.
The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.
The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.
Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence
Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer
15 Mar, 2023 | 15:11h | UTC
Press release | New technique reduces postoperative complications in prostate cancer surgery
14 Mar, 2023 | 13:33h | UTC
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
14 Mar, 2023 | 13:21h | UTC
RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
13 Mar, 2023 | 15:12h | UTCSummary: The study followed 1643 men diagnosed with localized prostate cancer (diagnosed by screening with PSA) in the United Kingdom between 1999 and 2009 who were randomly assigned to receive active monitoring, prostatectomy, or radiotherapy.
After a median follow-up of 15 years, the study found that while prostatectomy and radiotherapy decreased metastasis, local progression, and the need for long-term androgen deprivation therapy, death from prostate cancer was low regardless of the treatment assigned, with 17 deaths (3.1%) in the active-monitoring group, 12 deaths (2.2%) in the prostatectomy group, and 16 (2.9%) deaths in the radiotherapy group (P=0.53). Additionally, the study found that overall deaths were similar between the groups.
The authors suggest that the choice of therapy for localized prostate cancer involves weighing the benefits and harms associated with each treatment option.
Article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows – University of Bristol
Commentary on Twitter
Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) https://t.co/G2ABkMkyJg #oncology pic.twitter.com/s2Va08Fpxj
— NEJM (@NEJM) March 11, 2023
RCT/extended follow-up | Lenvatinib plus pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma
9 Mar, 2023 | 14:03h | UTCLenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW: In extended FU of the CLEAR trial (+7 mo), median PFS was 23·3 mo (95% CI 20·8–27·7) with first-line lenvatinib + pembrolizumab and 9·2 mo (6·0–11·0) with sunitinib (stratified HR 0·42, 95% CI 0·34–0·52) in pts w/ advanced renal cell carcinoma. #rccsmhttps://t.co/gbwBIIqSK8 pic.twitter.com/78OijM9Rtm
— The Lancet Oncology (@TheLancetOncol) February 28, 2023
Consensus Paper | Management of patients with advanced prostate cancer
7 Mar, 2023 | 13:02h | UTC